Albany Molecular Research, Inc. Announces Key Management, Staff Promotions.

Business Editors

ALBANY, N.Y.--(BUSINESS WIRE)--March 22, 2001

Albany Molecular Research, Inc. (Nasdaq: AMRI) Chairman and Chief Executive Officer Thomas E. D'Ambra, Ph.D. announced today a number (57) of recent staff promotions.

In management, James J. Grates has been promoted to the position of vice president, operations. Previously vice president of human resources, Mr. Grates will assume additional responsibilities for AMRI's non-scientific business operations at all of the company's locations, which include Albany, Rensselaer and Syracuse, NY; Iowa City, IA and Bothell, WA. Mr. Grates has served as vice president of human resources for AMRI since 1996, and played a key role in helping to bring about AMRI's growth from 69 total employees in January 1997 to over 370 employees today. Mr. Grates holds a B.S. in business administration from Utica College of Syracuse University.

Michael D. Ironside, Ph.D. was promoted to director of chemical development. In his new role, Dr. Ironside will direct the efforts of AMRI's Albany-based chemical development group, which conducts process research and scale-up activities on potential pharmaceutical compounds and intermediates. He will also oversee the company's GMP (Good Manufacturing Practices) group, which produces these compounds in accordance with stringent regulations established by the U.S. Food and Drug Administration (FDA). Since joining AMRI in 1998, Dr. Ironside has assumed increasing levels of responsibility, including an earlier promotion to assistant director of chemical development in June 2000. Dr. Ironside holds a Ph.D. in organic chemistry from Dundee University in Scotland and was a postdoctoral fellow at Sydney University in Australia.

Andrea M. Schulz has been promoted to director of human resources. Ms. Schulz will assume responsibility for oversight of AMRI's New York-based human resources activities, which include recruitment and retention programs, administration of employee benefits, organizational development, and other human resource-related matters. She previously held the position of human resources manager and has been with AMRI since 1997. Ms. Schulz earned a bachelor's degree in business administration from James Madison University.

Dan L. Lowenski has been named director of environmental health and safety. He has been AMRI's industrial hygiene/safety officer since 1996. Mr. Lowenski's new title recognizes the expansion of his responsibilities for environmental health and safety activities beyond AMRI's Albany area operations to include operations in Syracuse, Iowa and Washington state. Mr. Lowenski holds a B.S. in criminal justice from the State University of New York at Buffalo.

David M. Coon was promoted to director of facilities. Mr. Coon joined Albany Molecular Research, Inc. in 1997. In his expanding role, he continues responsibility for facilities management at all AMRI locations. During his tenure at AMRI, Mr. Coon has overseen expansions at AMRI's Iowa City, IA and Albany, Rensselaer and Syracuse, NY locations, including extensive renovations to the company's East Campus facilities in space formerly used by Sterling-Winthrop. Mr. Coon holds an A.O.S. in refrigeration, heating and air conditioning from Hudson Valley Community College.

Brian T. Gregg, Ph.D. was promoted to assistant director of combinatorial chemistry. Under his new title, Dr. Gregg will expand his role in managing AMRI's growing combinatorial chemistry efforts, which use automated robotic and miniaturization techniques to produce potential medicinal compounds at a rapid rate. Dr. Gregg joined AMRI in 1993 and since that time has been promoted to several positions of increasing responsibility, culminating in this most recent appointment. In his time at AMRI, Dr. Gregg has conducted research in a number of therapeutic areas and worked on numerous customer projects for the company. He earned a Ph.D. in chemistry from Rensselaer Polytechnic Institute.

William G. Earley, Ph.D. was promoted to section head, combinatorial chemistry. In recognition of his continuing contributions to the company's combinatorial chemistry efforts, Dr. Earley will take on additional management responsibilities in the department. Dr. Earley joined AMRI in 1997, bringing with him 14 years of experience in organic synthesis and medicinal chemistry, including eight years at the former Sterling-Winthrop Research Institute, both in Rensselaer, NY and Collegeville, PA. He earned a Ph.D. in chemistry from the University of Vermont and conducted postdoctoral research at the University of California, Irvine.

In addition, AMRI is proud to announce the promotion of the following individuals, in recognition of their efforts, contributions and professional growth:

      -- Feryan Ahmed, Ph.D. to senior research chemist I

      -- Sarah E. Brennan to senior human resources administrator

      -- Paul R. Bruzinski, Ph.D. to senior research chemist II

      -- Ronald N. Buckle, Ph.D. to senior research chemist I

      -- Lori C. Burry, Ph.D. to senior research chemist I

      -- Timothy S. Butcher to research chemist II

      -- Brian M. Cochran to research chemist II

      -- Dawn M. Davis to senior research chemist I

      -- Amy R. Dellio to laboratory technician

      -- Bryan C. Duffy, Ph.D. to senior research chemist I

      -- Scott A. Durivage to information technology administrator

      -- Polivina Jolicia F. Gauuan, Ph.D. to senior research chemist
       III

      -- Edward C. Gersten to research chemist II

      -- Brian P. Haney, Ph.D. to senior research chemist I

      -- Simon N. Haydar, Ph.D. to senior research chemist III

      -- Charles R. Heap, Ph.D. to senior research chemist I

      -- Hongjian Jiang, Ph.D. to senior research chemist I

      -- Kori B. Kaufman to business development associate

      -- Graham S. Knox to research chemist III

      -- Robert M. Lewis to research chemist II

      -- Junkai Liao, Ph.D. to senior research chemist I

      -- Benjamin J. Littler, Ph.D. to senior research chemist I

      -- David D. Manning, Ph.D. to senior research chemist II

      -- Jessica S. Mansmith to administrative assistant, communications
       & business development

      -- Michael J. Mayer, Ph.D. to senior research chemist I

      -- Liaqat Masih to laboratory technician

      -- Dacia M. Maynard to research chemist I

      -- Bingidimi I. Mobele, Ph.D. to senior research chemist I

      -- Charles H. Montgomery, Ph.D. to senior research chemist I

      -- Audrey L. Morra to research chemist III

      -- Kathleen J. Moyer to senior human resources administrator

      -- Lioudmila V. Mozhaeva, Ph.D. to research scientist III

      -- Debasis Patra, Ph.D. to senior research chemist I

      -- Michelle L. Pilato, Ph.D. to senior research chemist

      -- Jeffrey M. Ralph to research chemist II

      -- John E. Reilly, Ph.D. to senior research chemist III

      -- John M. Roosenberg, Ph.D. to senior research chemist I

      -- Kristin L. Schmitz to research chemist III

      -- Douglas G. Stafford, Ph.D. to senior research chemist

      -- Gerard H. Stapf to research chemist I

      -- Todd M. Stark, Ph.D. to senior research chemist I

      -- Priyantha M. Sugathapala, Ph.D. to senior research chemist I

      -- Mark P. Sweet, Ph.D. to senior research chemist I

      -- Scott R. Tweedie to research chemist II

      -- Luckner G. Ulysse, Jr., Ph.D. to senior research chemist II

      -- Paul F. Vogt, Ph.D. to senior research chemist III

      -- Mark A. Wolf, Ph.D. to senior research chemist III

      -- Michael J. Wyle to research chemist III

      -- Zhicai Yang, Ph.D. to senior research chemist I

      -- Pavel E. Zhichkin, Ph.D. to senior research chemist II

"I want to take this opportunity to congratulate each of these important employees on their promotions and achieving these career milestones, and to publicly thank them for their contributions to our success," said Dr. D'Ambra. "AMRI enjoyed another successful year of business in 2000. Clearly, that is attributable to the outstanding individuals at all levels of our organization. I look forward to working with them going forward."

Albany Molecular Research, Inc. is a leading chemistry research, drug discovery and development company focusing on applications for the life sciences industries. The company performs comprehensive chemistry research for many of the leading pharmaceutical and biotechnology companies and for its own internal research and development.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. The company's actual results may differ materially from such forward-looking statements. Factors that could cause such differences include, but are not limited to, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, sales of Allegra(R) (including any deviations in estimates provided by Aventis) and the company's receipt of significant royalties from the Allegra(R) license agreement, the company's ability to enforce its intellectual property and technology, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions, including its Bothell Research Center, to perform as expected, the company's ability to successfully complete its ongoing expansion projects on schedule and integrate acquired companies, and the company's ability to effectively manage its growth, as well as those discussed in the company's final prospectus as filed with the Securities and Exchange Commission on October 5, 2000 and in the company's other SEC filings.